重磅！Brooks Automation将以30亿美金出售半导体业务，所得收益加速生命科学业务增长
BROOKS AUTOMATION宣布将半导体解决方案集团业务出售给THOMAS H.LEE PARTNERS。Thomas H.Lee Partners将出资30亿美元现金收购该业务，Brooks所得交易收益将用于加速生命科学业务的增长。
马萨诸塞州切姆斯福德，2021年9月20日讯。金唯智母公司Brooks Automation, Inc.（纳斯达克代码：BRKS）今天宣布，以30亿美元现金将其半导体解决方案集团业务（或“自动化业务”）出售给Thomas H.Lee Partners，L.P.（“THL”），并已签订最终协议。在截至2021年6月30日的过去12个月内，自动化业务报告的收入约为6.13亿美元。购买价格可根据营运资金和其他项目进行调整。Brooks集团预计，在满足常规交割条件和监管批准后，交易将于2022年上半年结束。
Brooks的自动化业务是全球半导体自动化设备行业高精度、高通量真空机器人和系统以及污染控制解决方案的领先供应商。近期，该业务已扩展到多市场应用的协作机器人。
Brooks总裁兼首席执行官Steve Schwartz表示：“我们为自己建立的高度创新的自动化业务感到自豪，该业务在半导体行业取得了巨大成功。我们期待着它在THL的领导下继续增长。同样的，我们为生命科学业务的实力感到自豪，也为这笔交易的巨大收益感到兴奋，这笔交易将为拥有巨大机遇的生命科学市场提供战略投资。”
THL董事总经理Michael Kaczmarek表示：“在过去40年中，Brooks建立了一系列卓越的自动化解决方案，解决了半导体设备行业面临的某些最困难的工程挑战。我们很高兴能够支持该业务在半导体及其它领域的新增长阶段。”
THL自动化基金董事总经理兼负责人Jim Carlisle表示：“THL一直专注于投资于自动化领导者，正如我们在2020年成立自动化基金所强调的那样，与行业领导者合作以加速增长。我们欢迎Brooks Automation和多市场协作自动化团队加入我们充满活力和创新的自动化解决方案供应商大家庭，期待与Brooks Automation的优秀团队合作，发掘新的增长机会。”
由于半导体业务即将出售给THL，Brooks将不再执行2021年5月宣布的计划，即将集团拆分为两个独立的上市公司。预计在 2022 年上半年完成出售后，半导体自动化业务将与Brooks Automation的名称和品牌一起转移到给THL。剩下的生命科学业务将作为独立的生命科学上市公司运营，新名称将于近期公布。Brooks管理层计划于 2021 年 11 月 16 日举办投资者日，讨论生命科学业务。
本次交易由Evercore担任独家财务顾问，Mintz、Levin、Cohn、Ferris、Glovsky和Popeo，P.C.担任Brooks Automation的法律顾问。
关于 Brooks Automation
Brooks（纳斯达克：BRKS）运营 Life Sciences 和 Semiconductor Solutions 两项全球性市场领先业务，均有其各自的重点和专长领域。Life Sciences 为全球顶级制药、生物技术、学术和医疗机构提供全套可靠的冷链样品管理解决方案和基因组服务，涵盖药物开发、临床研究和先进细胞疗法等领域。作为半导体制造业 40 多年的合作伙伴，Brooks 的 Semiconductor Solutions 企业为全球领先的半导体芯片制造商和设备制造商提供行业领先的精密真空机器人技术、集成自动化系统和污染控制解决方案，以及多市场应用的协作式机器人技术和自动化能力。Brooks 总部位于马萨诸塞州切姆斯福德，业务遍及北美、欧洲和亚洲。更多信息，请访问www.Brooks.com。
关于Thomas H.Lee Partners
Thomas H.Lee Partners，L.P.（“THL”）是一家领先的私募股权公司，专注投资于三个领域的中等市场增长型公司：金融服务、医疗保健和技术与商业解决方案。THL将深厚的行业专业知识与专业的内部运营资源结合起来，与管理层合作，改造和建立具有持久价值的伟大公司。公司的领域专业知识和资源有助于建立伟大的公司，以加速增长、改善运营并推动长期可持续价值。自1974年以来，THL已经筹集了300多亿美元的股本，投资了160多家公司，并完成了500多次附加收购，收购时的企业总价值收购超过2100亿美元。THL通过其旗舰私募股权基金和专门的自动化基金投资自动化公司。更多信息，请访问www.THL.com。
1934年《证券交易法》第21E节项下的“安全港声明”
本新闻稿中的一些声明是根据1934年《证券交易法》第21E条做出的前瞻性声明。这些声明既不是承诺也不是担保，且涉及已知或未知的风险和不确定性，可能导致Brooks的财务和业务结果与我们的预期存在重大差异。它们基于管理层在制定时已知的事实。这些前瞻性陈述包括但不限于关于我们将半导体自动化业务出售给 THL 的确定性和/或完成时间、我们投资预期现金收益的能力以及我们的生命科学业务预期增长前景的声明。可能导致结果与我们预期不同的因素包括意外延迟获得监管批准或满足其他惯例成交条件；缺乏可用的战略收购来支持生命科学的发展； COVID-19 全球大流行对我们所服务的市场（包括我们的供应链）以及整个全球经济的持续影响；全球政治和经济状况的不确定性，以及其他因素和其他风险，包括我们在向美国证券交易委员会提交的文件中描述的风险，包括但不限于我们的 10-K 表格年度报告、8 表格的当前报告-K 和我们关于 Form 10-Q 的季度报告。因此，我们无法保证我们未来的结果不会与预期的结果存在重大差异。 Brooks 明确不承担任何义务或承诺公开发布任何此类声明的任何更新或修订，以反映我们预期的任何变化或任何此类声明所依据的事件、条件或情况的任何变化。 Brooks 不承担更新本新闻稿中包含的信息的义务。
英文原文：
CHELMSFORD, Mass., September 20, 2021 (PRNEWSWIRE) — Brooks Automation, Inc. (Nasdaq: BRKS) today announced that it has entered into a definitive agreement to sell its Semiconductor Solutions Group business (or “automation business”) to Thomas H. Lee Partners, L.P. (“THL”) for $3.0 billion in cash. The automation business reported approximately $613 million in revenue in the last twelve months ended June 30, 2021. The purchase price is subject to adjustments for working capital and other items. Brooks anticipates closing of the transaction in the first half of calendar year 2022 upon satisfaction of customary closing conditions and regulatory approvals.
Brooks’ automation business is a leading provider of high precision, high throughput vacuum robots and systems as well as contamination control solutions to the global semiconductor capital equipment industry. Recently, the business expanded into collaborative robotics for multi-market applications.
“We are proud of the highly innovative automation business that we have built, which has seen great success in the semiconductor industry. We look forward to its continued growth under THL’s ownership” stated Steve Schwartz, President and CEO of Brooks. “We are equally proud of the strength and growth of our life sciences business and excited by the significant proceeds from this transaction which will afford strategic investments in a market where we see tremendous opportunity.”
“Over the past 40 years, Brooks has built an impressive portfolio of automated solutions to address some of the most difficult engineering challenges facing the semiconductor capital equipment industry,” stated Michael Kaczmarek, Managing Director, THL. “We are excited to support the business in its next leg of growth in semiconductor and beyond.”
Jim Carlisle, Managing Director and Head of THL’s Automation Fund, said: “THL remains focused on investing behind automation leaders, as underscored by the establishment of our Automation Fund in 2020, and working with management to accelerate growth. We welcome the Brooks semiconductor and multi-market collaborative automation team into our family of dynamic and innovative automation solution providers, and we look forward to partnering with the talented team from Brooks Automation to unlock new growth opportunities.”
As a result of the pending sale to THL, Brooks will no longer pursue a separation into two independent and publicly traded companies as announced in May 2021. Following completion of the sale, expected in first half of 2022, the semiconductor automation business will transition to the ownership of THL along with the Brooks Automation name and brand. The remaining life sciences business will then operate as a standalone publicly traded life sciences company, under a new name to be announced in the near future. Management will host an investor day to discuss the life sciences business on November 16, 2021.
In connection with the transaction, Evercore acted as the exclusive financial advisor and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. acted as legal counsel to Brooks Automation.
Management will host a conference call this morning at 8:30 a.m. Eastern Time, Monday, September 20th, 2021 to discuss the transaction and to host a question and answer session. To participate in the conference call, please dial 800-582-1443 for domestic callers and +1-212-231-2926 for international callers.
The call will be webcast live over the Internet and, together with presentation materials referenced on the call, will be hosted at the Investor Relations section of Brooks’ website at https://brooks.investorroom.com, and will be archived online on this website for convenient on-demand replay.
About Brooks Automation
Brooks (Nasdaq: BRKS) operates two global, market-leading businesses, Life Sciences and Semiconductor Solutions, each with its own distinct area of focus and expertise. The Life Sciences business provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry’s top pharmaceutical, biotech, academic and healthcare institutions globally. With over 40 years as a partner to the semiconductor manufacturing industry, Brooks’ Semiconductor Solutions business provides industry-leading precision vacuum robotics, integrated automation systems and contamination control solutions to the world’s leading semiconductor chip makers and equipment manufacturers as well as collaborative robotics and automation capabilities for multi-market applications. Brooks is headquartered in Chelmsford, MA, with operations in North America, Europe and Asia. For more information, please visit www.brooks.com.
About Thomas H. Lee Partners
Thomas H. Lee Partners, L.P. (“THL”) is a premier private equity firm investing in middle market growth companies exclusively in three sectors: Financial Services, Healthcare and Technology & Business Solutions. THL couples deep sector expertise with dedicated internal operating resources to transform and build great companies of lasting value in partnership with management. The Firm’s domain expertise and resources help to build great companies with an aim to accelerate growth, improve operations and drive long-term sustainable value. Since 1974, THL has raised more than $30 billion of equity capital, invested in over 160 companies and completed more than 500 add-on acquisitions representing an aggregate enterprise value at acquisition of over $210 billion. THL invests in automation companies through its flagship private equity fund and a dedicated automation fund. For more information, please visit www.thl.com.
“Safe Harbor Statement” under Section 21E of the Securities Exchange Act of 1934
Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Brooks’ financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. These forward-looking statements include but are not limited to statements about the certainty and/or timing of completion of the pending sale of our semiconductor automation business to THL, our ability to invest the expected cash proceeds from the sale, and the anticipated growth prospects of our life sciences business. Factors that could cause results to differ from our expectations include unexpected delays in obtaining regulatory approvals or satisfaction of other customary closing conditions; a lack of available strategic acquisitions to support life sciences growth; continued impact of the COVID-19 global pandemic on the markets we serve, including our supply chain, and on the global economy generally; uncertainties in global political and economic conditions, and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, current reports on Form 8-K and our quarterly reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Brooks expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based. Brooks undertakes no obligation to update the information contained in this press release.
INVESTOR CONTACTS:
Sara Silverman
Director, Investor Relations
Brooks Automation
978.262.2635
sara.silverman@brooks.com
Sherry Dinsmore
Brooks Automation
978.262.2400
sherry.dinsmore@brooks.com
